222 related articles for article (PubMed ID: 31782984)
41. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
42. Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.
Leruez-Ville M; Seng R; Morand P; Boufassa F; Boue F; Deveau C; Rouzioux C; Goujard C; Seigneurin JM; Meyer L
HIV Med; 2012 Sep; 13(8):479-87. PubMed ID: 22414000
[TBL] [Abstract][Full Text] [Related]
43. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
[TBL] [Abstract][Full Text] [Related]
44. AIDS-related lymphoma in Brazil. Histopathology, immunophenotype, and association with Epstein-Barr virus.
Bacchi CE; Bacchi MM; Rabenhorst SH; Soares FA; Fonseca LE; Barbosa HS; Weiss LM; Gown AM
Am J Clin Pathol; 1996 Feb; 105(2):230-7. PubMed ID: 8607450
[TBL] [Abstract][Full Text] [Related]
45. The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH.
Liang JH; Lu L; Zhu HY; Li W; Fan L; Li JY; Xu W
Cancer Res Treat; 2019 Jan; 51(1):150-157. PubMed ID: 29621877
[TBL] [Abstract][Full Text] [Related]
46. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.
Au WY; Pang A; Choy C; Chim CS; Kwong YL
Blood; 2004 Jul; 104(1):243-9. PubMed ID: 15031209
[TBL] [Abstract][Full Text] [Related]
47. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients.
Spacek M; Hubacek P; Markova J; Zajac M; Vernerova Z; Kamaradova K; Stuchly J; Kozak T
APMIS; 2011 Jan; 119(1):10-6. PubMed ID: 21143522
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly.
Adam P; Bonzheim I; Fend F; Quintanilla-Martínez L
Adv Anat Pathol; 2011 Sep; 18(5):349-55. PubMed ID: 21841405
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus (EBV) provides survival factors to EBV
Wu L; Ehlin-Henriksson B; Zhou X; Zhu H; Ernberg I; Kis LL; Klein G
Immunology; 2017 Dec; 152(4):562-573. PubMed ID: 28699226
[TBL] [Abstract][Full Text] [Related]
50. Plasma Epstein Barr viral load in adult-onset Hodgkin lymphoma in South India.
Sinha M; Rao CR; Shafiulla M; Shankaranand B; Viveka BK; Lakshmaiah KC; Jacob LA; Babu GK; Jayshree RS
Hematol Oncol Stem Cell Ther; 2016 Mar; 9(1):8-13. PubMed ID: 26657995
[TBL] [Abstract][Full Text] [Related]
51. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
52. TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients.
Cho J; Kim E; Yoon SE; Kim SJ; Kim WS
Cancer; 2023 May; 129(10):1502-1512. PubMed ID: 36812290
[TBL] [Abstract][Full Text] [Related]
53. Utility of Epstein-Barr Viral Load in Blood for Diagnosing and Predicting Prognosis of Lymphoma: A Comparison with Epstein-Barr Virus-Encoded RNA in Situ Hybridization.
Song J; Kim JY; Kim S; Park Y
J Mol Diagn; 2022 Sep; 24(9):977-991. PubMed ID: 35718093
[TBL] [Abstract][Full Text] [Related]
54. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.
Castillo JJ; Beltran BE; Miranda RN; Paydas S; Winer ES; Butera JN
Oncologist; 2011; 16(1):87-96. PubMed ID: 21212426
[TBL] [Abstract][Full Text] [Related]
55. Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.
Zhao XF; Zhao MY; Chai L; Kukuruga D; Tan M; Stass SA
Int J Clin Exp Pathol; 2013; 6(2):148-54. PubMed ID: 23330000
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
Lei KI; Chan LY; Chan WY; Johnson PJ; Lo YM
Clin Cancer Res; 2002 Jan; 8(1):29-34. PubMed ID: 11801537
[TBL] [Abstract][Full Text] [Related]
57. Genetic and immunohistochemical characterization of Epstein-Barr virus-associated diffuse large B-cell lymphoma.
Al-Humood S; Alqallaf A; Al-Shemmari S; Al-Faris L; Al-Ayadhy B
Acta Haematol; 2014; 131(1):1-10. PubMed ID: 24008861
[TBL] [Abstract][Full Text] [Related]
58. Plasma Epstein Barr virus (EBV) DNA as a biomarker for EBV associated Hodgkin lymphoma.
Dinand V; Sachdeva A; Datta S; Bhalla S; Kalra M; Wattal C; Radhakrishnan N
Indian Pediatr; 2015 Aug; 52(8):681-5. PubMed ID: 26388626
[TBL] [Abstract][Full Text] [Related]
59. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
[TBL] [Abstract][Full Text] [Related]
60. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
